Previous 10 | Next 10 |
The FDA's Office of Pharmaceutical Quality has requested stability data on Clearside Biomedical's (NASDAQ: CLSD ) XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) that was made with an enhanced manufacturing process although the formulation has not changed. OPQ wants t...
ALPHARETTA, Ga., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update regard...
Gainers : Corindus Vascular Robotics (NYSEMKT: CVRS ) +76% . Vitamin Shoppe (NYSE: VSI ) +41% . Avedro (NASDAQ: AVDR ) +36% . G1 Therapeutics (NASDAQ: GTHX ) +27% . Alpha and Omega Semiconductor (NASDAQ: AOSL ) +22% . Carvana (NYSE: CVNA ) +21% . Roku (NASDAQ: ROKU ) +20% ...
Thinly traded nano cap Clearside Biomedical ( CLSD +17% ) is up on almost double normal volume, albeit on turnover of only 588K shares, following its Q2 report released after the close yesterday. Highlights: More news on: Clearside Biomedical, Inc., Healthcare stocks news, Earnings new...
Clearside Biomedical Inc. (CLSD) Q2 2019 Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Jenny Kobin – Investor Relations George Lasezkay – Chief Executive Officer Tom Ciulla – Chief Medical Officer Charlie Deignan – Chief Fin...
Clearside Biomedical (NASDAQ: CLSD ): Q2 GAAP EPS of -$0.15 beats by $0.25 . More news on: Clearside Biomedical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Strategic Focus on Building Internal Pipeline and External Collaborations Based on Suprachoroidal Space Injection Platform - - Clearside Plans to Out-License XIPERE ™ - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga....
ALPHARETTA, Ga., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Med...
ALPHARETTA, Ga., July 31, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its second quarter 2019 financial resu...
- Suprachoroidal Space injections can be easily conducted in physicians’ offices as a potentially useful method of ocular distribution of drug to target back of the eye diseases - ALPHARETTA, Ga., July 31, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...